vs

Side-by-side financial comparison of Indonesia Energy Corp Ltd (INDO) and INVO Fertility, Inc. (IVF). Click either name above to swap in a different company.

INVO Fertility, Inc. is the larger business by last-quarter revenue ($1.8M vs $1.4M, roughly 1.2× Indonesia Energy Corp Ltd). INVO Fertility, Inc. runs the higher net margin — -150.5% vs -195.5%, a 45.0% gap on every dollar of revenue. On growth, INVO Fertility, Inc. posted the faster year-over-year revenue change (22.6% vs 0.0%).

PT Kino Indonesia Tbk, formerly PT Kinocare Era Kosmetindo, or simply known as Kino, is an Indonesian multinational consumer goods company headquartered in Tangerang, Banten, founded in 1999 by Harry Sanusi. It specializes the manufacturing of its products in the wide range of personal care, hygiene, health care, confectionery, pastry, beverages, and pet care. As of 2022, the company is currently led by Sidharta Prawira Oetama as its president director while Sanusi act as its president commis...

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

INDO vs IVF — Head-to-Head

Bigger by revenue
IVF
IVF
1.2× larger
IVF
$1.8M
$1.4M
INDO
Growing faster (revenue YoY)
IVF
IVF
+22.6% gap
IVF
22.6%
0.0%
INDO
Higher net margin
IVF
IVF
45.0% more per $
IVF
-150.5%
-195.5%
INDO

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
INDO
INDO
IVF
IVF
Revenue
$1.4M
$1.8M
Net Profit
$-2.8M
$-2.6M
Gross Margin
Operating Margin
-167.8%
-93.1%
Net Margin
-195.5%
-150.5%
Revenue YoY
0.0%
22.6%
Net Profit YoY
-34.5%
-62.2%
EPS (diluted)
$-0.19
$-0.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INDO
INDO
IVF
IVF
Q3 25
$1.8M
Q2 25
$1.4M
$1.9M
Q1 25
$1.6M
Q4 24
$1.7M
Q3 24
$1.4M
Q2 24
$1.8M
$1.8M
Q1 24
$1.6M
Q4 23
$1.4M
Net Profit
INDO
INDO
IVF
IVF
Q3 25
$-2.6M
Q2 25
$-2.8M
$-5.3M
Q1 25
$-17.4M
Q4 24
$-3.6M
Q3 24
$-1.6M
Q2 24
$-2.1M
$-2.2M
Q1 24
$-1.6M
Q4 23
$-2.0M
Gross Margin
INDO
INDO
IVF
IVF
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
31.0%
Q2 24
53.1%
Q1 24
45.3%
Q4 23
33.0%
Operating Margin
INDO
INDO
IVF
IVF
Q3 25
-93.1%
Q2 25
-167.8%
-160.4%
Q1 25
-1042.1%
Q4 24
-202.0%
Q3 24
-90.7%
Q2 24
-102.7%
-100.9%
Q1 24
-95.7%
Q4 23
-109.2%
Net Margin
INDO
INDO
IVF
IVF
Q3 25
-150.5%
Q2 25
-195.5%
-283.6%
Q1 25
-1060.1%
Q4 24
-211.3%
Q3 24
-113.8%
Q2 24
-114.0%
-122.2%
Q1 24
-101.3%
Q4 23
-144.4%
EPS (diluted)
INDO
INDO
IVF
IVF
Q3 25
$-0.77
Q2 25
$-0.19
$-13.30
Q1 25
$-12.53
Q4 24
$14.86
Q3 24
$-15.11
Q2 24
$-0.26
$-22.39
Q1 24
$-7.55
Q4 23
$-59.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INDO
INDO
IVF
IVF
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$21.9M
$5.8M
Total Assets
$25.2M
$18.8M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Total Debt
INDO
INDO
IVF
IVF
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
INDO
INDO
IVF
IVF
Q3 25
$5.8M
Q2 25
$21.9M
$2.6M
Q1 25
$3.3M
Q4 24
$12.7M
Q3 24
$-23.3K
Q2 24
$13.1M
$1.4M
Q1 24
$10.2K
Q4 23
$892.8K
Total Assets
INDO
INDO
IVF
IVF
Q3 25
$18.8M
Q2 25
$25.2M
$19.3M
Q1 25
$31.7M
Q4 24
$46.4M
Q3 24
$17.0M
Q2 24
$17.5M
$17.8M
Q1 24
$17.3M
Q4 23
$18.5M
Debt / Equity
INDO
INDO
IVF
IVF
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INDO
INDO
IVF
IVF
Operating Cash FlowLast quarter
$-2.5M
$-1.8M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-101.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INDO
INDO
IVF
IVF
Q3 25
$-1.8M
Q2 25
$-2.5M
$-1.7M
Q1 25
$-3.5M
Q4 24
$-617.4K
Q3 24
$-640.8K
Q2 24
$-700.9K
$-1.5M
Q1 24
$-260.6K
Q4 23
$-714.9K
Free Cash Flow
INDO
INDO
IVF
IVF
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
Q2 24
$-1.5M
Q1 24
$-310.3K
Q4 23
FCF Margin
INDO
INDO
IVF
IVF
Q3 25
-101.6%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
Q1 24
-19.7%
Q4 23
Capex Intensity
INDO
INDO
IVF
IVF
Q3 25
0.5%
Q2 25
0.5%
Q1 25
0.9%
Q4 24
4.6%
Q3 24
0.0%
Q2 24
3.0%
Q1 24
3.2%
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons